Who Gets Tigecycline-Induced Liver Damage Most Often?
Tigecycline, an antibiotic used for complicated infections, carries a black box warning for increased mortality risk, but liver damage (hepatotoxicity) manifests as elevated liver enzymes, acute hepatitis, or cholestasis in susceptible patients. Risk rises with higher doses or prolonged use beyond recommended durations (typically 14 days). Clinical data show incidence of severe liver injury at 1-2% overall, but higher in vulnerable groups.[1]
Patients with Pre-Existing Liver Disease
Those with chronic liver conditions like cirrhosis, hepatitis B/C, or non-alcoholic fatty liver disease face amplified risk. Tigecycline is metabolized hepatically and excreted via bile, leading to accumulation and toxicity in impaired livers. Trials report transaminase elevations >10x upper limit in up to 5% of cirrhotics versus <1% in healthy livers.[2][3]
Elderly or Frail Patients
Adults over 65, especially in ICU settings with sepsis or ventilator-associated pneumonia, show higher rates. Age-related reduced clearance combines with polypharmacy (e.g., concurrent hepatotoxins like vancomycin), doubling hepatotoxicity odds. Post-marketing reports note fatal liver failure in 0.5% of elderly cases.[1][4]
People on Multiple Hepatotoxic Drugs
Concurrent use with drugs like acetaminophen, azoles, or statins heightens risk through additive injury. Tigecycline's inhibition of bile salt export pumps (similar to cholestatic agents) worsens this. Case series identify 20-30% of severe events in polypharmacy scenarios.[3][5]
Obese or Critically Ill ICU Patients
Obesity alters tigecycline pharmacokinetics, requiring dose adjustments; unadjusted high doses (>100mg loading) correlate with 3x higher enzyme spikes. Critically ill patients with multi-organ failure or shock also accumulate the drug due to poor perfusion.[2][6]
Genetic or Metabolic Factors
Patients with polymorphisms in CYP3A4/5 (tigecycline metabolizers) or ABCB11 (bile transporter) genes may have slower clearance, though routine testing isn't standard. Rare reports link UGT1A1 variants (as in Gilbert's syndrome) to prolonged jaundice.[5]
Monitoring and Avoidance Strategies
Liver function tests are recommended at baseline, daily in high-risk patients, and upon enzyme elevations >5x normal—discontinue if persistent. Alternatives like eravacycline or meropenem are preferred for liver-impaired cases. No specific population is immune, but risks cluster in the above groups per FDA labeling.[1][4]
Sources:
[1] FDA Tigecycline Label
[2] Hepatology Journal Review on Tigecycline Hepatotoxicity
[3] Clinical Infectious Diseases Case Series
[4] Drugs.com Tigecycline Side Effects
[5] Pharmacotherapy Journal on Drug Interactions
[6] Critical Care Medicine ICU Data